ArticlePloS one2025
Role of endothelial cell markers in prognosis of hepatocellular carcinoma: Integrating bioinformatics analysis and experimental validation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated bioinformatic evaluation unveils a cellular senescence gene signature as a poor prognostic factor in hepatocellular carcinoma.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly prevalent malignancy with poor prognosis. Endothelial cells (ECs) play a crucial role in HCC progression, yet their involvement at the single-cell level remains underexplored. This study aimed to identify ECs-specific markers and develop a prognostic multi-gene signature for HCC using single-cell RNA sequencing (scRNA-seq). MATERIALS AND
methodsSingle-cell transcriptomic data from 12 HCC samples were analyzed to identify EC-associated genes. A prognostic gene signature was constructed using Lasso-Cox regression analysis based on The Cancer Genome Atlas (TCGA) cohort and subsequently validated using an independent cohort from the International Cancer Genome Consortium (ICGC). Immunohistochemistry (IHC) and Western blotting were employed to experimentally validate gene expression in tissue samples.
resultsFive EC-specific genes-NDRG1, HBEGF, FKBP1A, KLRB1, and FDPS-were identified as prognostic markers. The resulting multi-gene signature effectively stratified patients into high- and low-risk groups, with significant differences in overall survival. Validation in the ICGC cohort confirmed the model's predictive performance. IHC and Western blotting results further confirmed the elevated expression of these genes in HCC tissues.
conclusionsThis study established an EC-related prognostic signature that accurately predicts HCC prognosis. The identified markers may aid early diagnosis and serve as potential therapeutic targets for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.